{"id":64121,"date":"2026-04-28T11:51:49","date_gmt":"2026-04-28T03:51:49","guid":{"rendered":"https:\/\/flcube.com\/?p=64121"},"modified":"2026-04-28T11:51:50","modified_gmt":"2026-04-28T03:51:50","slug":"eli-lilly-to-acquire-ajax-therapeutics-for-up-to-2-3-billion-to-expand-jak-inhibitor-portfolio-in-myeloproliferative-neoplasms","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=64121","title":{"rendered":"Eli Lilly to Acquire Ajax Therapeutics for Up to $2.3 Billion to Expand JAK Inhibitor Portfolio in Myeloproliferative Neoplasms"},"content":{"rendered":"\n<p><strong>Eli Lilly and Company<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/LLY:NYSE\">NYSE: LLY<\/a>) and <strong>Ajax Therapeutics, Inc.<\/strong> announced a definitive agreement on April 27, 2026, under which <strong>Lilly will acquire Ajax<\/strong> for up to <strong>USD 2.3 billion<\/strong> in cash, including an upfront payment and milestone-based clinical and regulatory achievements.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-transaction-details\">Transaction Details<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Component<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Acquirer<\/strong><\/td><td>Eli Lilly and Company (NYSE: LLY)<\/td><\/tr><tr><td><strong>Target<\/strong><\/td><td>Ajax Therapeutics, Inc.<\/td><\/tr><tr><td><strong>Total Consideration<\/strong><\/td><td>Up to USD 2.3 billion in cash<\/td><\/tr><tr><td><strong>Structure<\/strong><\/td><td>Upfront payment + clinical\/regulatory milestones<\/td><\/tr><tr><td><strong>Announcement Date<\/strong><\/td><td>April 27, 2026<\/td><\/tr><tr><td><strong>Therapeutic Focus<\/strong><\/td><td>Myeloproliferative neoplasms (MPNs)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-ajax-pipeline-amp-strategic-rationale\">Ajax Pipeline &amp; Strategic Rationale<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Lead Asset<\/strong>: AJ1-11095, investigational once-daily oral <strong>Type II JAK2 inhibitor<\/strong><\/li>\n\n\n\n<li><strong>Innovation<\/strong>: <strong>First-in-class<\/strong> mechanism targeting JAK2 with Type II binding conformation<\/li>\n\n\n\n<li><strong>Clinical Stage<\/strong>: Currently in <strong>Phase 1 trial (AJX-101)<\/strong> evaluating patients with myelofibrosis previously treated with Type I JAK2 inhibitors<\/li>\n\n\n\n<li><strong>Patient Population<\/strong>: Addresses unmet need in MPN patients who have developed resistance or intolerance to existing Type I JAK inhibitors<\/li>\n\n\n\n<li><strong>Strategic Fit<\/strong>: Complements Lilly&#8217;s existing oncology portfolio and expands presence in hematological malignancies<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-development-status\">Clinical Development Status<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Trial Designation<\/th><th>AJX-101<\/th><\/tr><\/thead><tbody><tr><td><strong>Phase<\/strong><\/td><td>Phase 1<\/td><\/tr><tr><td><strong>Patient Population<\/strong><\/td><td>Myelofibrosis patients previously treated with Type I JAK2 inhibitors<\/td><\/tr><tr><td><strong>Dosing Regimen<\/strong><\/td><td>Once-daily oral administration<\/td><\/tr><tr><td><strong>Mechanism Differentiation<\/strong><\/td><td>Type II JAK2 inhibition vs. standard Type I inhibitors<\/td><\/tr><tr><td><strong>Therapeutic Rationale<\/strong><\/td><td>Potential to overcome limitations of current JAK inhibitor therapies<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context-amp-competitive-landscape\">Market Context &amp; Competitive Landscape<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Myelofibrosis Market<\/strong>: Limited treatment options for patients progressing on or intolerant to existing JAK inhibitors<\/li>\n\n\n\n<li><strong>JAK Inhibitor Evolution<\/strong>: Type II inhibitors represent next-generation approach with potential for improved selectivity and reduced side effects<\/li>\n\n\n\n<li><strong>Lilly&#8217;s Oncology Strategy<\/strong>: Acquisition aligns with Lilly&#8217;s focus on targeted therapies and precision medicine in oncology<\/li>\n\n\n\n<li><strong>Pipeline Synergies<\/strong>: Potential to combine with Lilly&#8217;s existing assets and development expertise<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financial-amp-strategic-implications\">Financial &amp; Strategic Implications<\/h2>\n\n\n\n<p>The acquisition represents a significant bet by Lilly on the next generation of JAK inhibitors, with the substantial milestone payments reflecting confidence in AJ1-11095&#8217;s clinical potential. The deal provides Ajax shareholders with attractive upside while giving Lilly access to a differentiated asset that could address a critical gap in MPN treatment paradigms.<\/p>\n\n\n\n<p>For Lilly, this acquisition strengthens its position in the competitive JAK inhibitor space and demonstrates continued commitment to expanding its oncology pipeline through strategic acquisitions of innovative biotechnology companies.<\/p>\n\n\n\n<p><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding the acquisition, clinical development, and financial terms. Actual outcomes may differ due to risks including regulatory approvals, clinical trial results, and integration challenges.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Eli Lilly and Company (NYSE: LLY) and Ajax Therapeutics, Inc. announced a definitive agreement on&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[1],"tags":[4717,199,911],"class_list":["post-64121","post","type-post","status-publish","format-standard","hentry","category-uncategorized","tag-ajax-therapeutics","tag-eli-lilly","tag-nyse-lly"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Eli Lilly to Acquire Ajax Therapeutics for Up to $2.3 Billion to Expand JAK Inhibitor Portfolio in Myeloproliferative Neoplasms - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Eli Lilly and Company (NYSE: LLY) and Ajax Therapeutics, Inc. announced a definitive agreement on April 27, 2026, under which Lilly will acquire Ajax for up to USD 2.3 billion in cash, including an upfront payment and milestone-based clinical and regulatory achievements.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=64121\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Eli Lilly to Acquire Ajax Therapeutics for Up to $2.3 Billion to Expand JAK Inhibitor Portfolio in Myeloproliferative Neoplasms\" \/>\n<meta property=\"og:description\" content=\"Eli Lilly and Company (NYSE: LLY) and Ajax Therapeutics, Inc. announced a definitive agreement on April 27, 2026, under which Lilly will acquire Ajax for up to USD 2.3 billion in cash, including an upfront payment and milestone-based clinical and regulatory achievements.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=64121\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-28T03:51:49+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-28T03:51:50+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64121#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64121\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Eli Lilly to Acquire Ajax Therapeutics for Up to $2.3 Billion to Expand JAK Inhibitor Portfolio in Myeloproliferative Neoplasms\",\"datePublished\":\"2026-04-28T03:51:49+00:00\",\"dateModified\":\"2026-04-28T03:51:50+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64121\"},\"wordCount\":409,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Ajax Therapeutics\",\"Eli Lilly\",\"NYSE: LLY\"],\"articleSection\":[\"Others\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=64121#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64121\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=64121\",\"name\":\"Eli Lilly to Acquire Ajax Therapeutics for Up to $2.3 Billion to Expand JAK Inhibitor Portfolio in Myeloproliferative Neoplasms - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-04-28T03:51:49+00:00\",\"dateModified\":\"2026-04-28T03:51:50+00:00\",\"description\":\"Eli Lilly and Company (NYSE: LLY) and Ajax Therapeutics, Inc. announced a definitive agreement on April 27, 2026, under which Lilly will acquire Ajax for up to USD 2.3 billion in cash, including an upfront payment and milestone-based clinical and regulatory achievements.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64121#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=64121\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=64121#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Eli Lilly to Acquire Ajax Therapeutics for Up to $2.3 Billion to Expand JAK Inhibitor Portfolio in Myeloproliferative Neoplasms\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Eli Lilly to Acquire Ajax Therapeutics for Up to $2.3 Billion to Expand JAK Inhibitor Portfolio in Myeloproliferative Neoplasms - Insight, China&#039;s Pharmaceutical Industry","description":"Eli Lilly and Company (NYSE: LLY) and Ajax Therapeutics, Inc. announced a definitive agreement on April 27, 2026, under which Lilly will acquire Ajax for up to USD 2.3 billion in cash, including an upfront payment and milestone-based clinical and regulatory achievements.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=64121","og_locale":"en_US","og_type":"article","og_title":"Eli Lilly to Acquire Ajax Therapeutics for Up to $2.3 Billion to Expand JAK Inhibitor Portfolio in Myeloproliferative Neoplasms","og_description":"Eli Lilly and Company (NYSE: LLY) and Ajax Therapeutics, Inc. announced a definitive agreement on April 27, 2026, under which Lilly will acquire Ajax for up to USD 2.3 billion in cash, including an upfront payment and milestone-based clinical and regulatory achievements.","og_url":"https:\/\/flcube.com\/?p=64121","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-04-28T03:51:49+00:00","article_modified_time":"2026-04-28T03:51:50+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=64121#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=64121"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Eli Lilly to Acquire Ajax Therapeutics for Up to $2.3 Billion to Expand JAK Inhibitor Portfolio in Myeloproliferative Neoplasms","datePublished":"2026-04-28T03:51:49+00:00","dateModified":"2026-04-28T03:51:50+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=64121"},"wordCount":409,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Ajax Therapeutics","Eli Lilly","NYSE: LLY"],"articleSection":["Others"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=64121#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=64121","url":"https:\/\/flcube.com\/?p=64121","name":"Eli Lilly to Acquire Ajax Therapeutics for Up to $2.3 Billion to Expand JAK Inhibitor Portfolio in Myeloproliferative Neoplasms - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-04-28T03:51:49+00:00","dateModified":"2026-04-28T03:51:50+00:00","description":"Eli Lilly and Company (NYSE: LLY) and Ajax Therapeutics, Inc. announced a definitive agreement on April 27, 2026, under which Lilly will acquire Ajax for up to USD 2.3 billion in cash, including an upfront payment and milestone-based clinical and regulatory achievements.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=64121#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=64121"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=64121#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Eli Lilly to Acquire Ajax Therapeutics for Up to $2.3 Billion to Expand JAK Inhibitor Portfolio in Myeloproliferative Neoplasms"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/64121","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=64121"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/64121\/revisions"}],"predecessor-version":[{"id":64122,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/64121\/revisions\/64122"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=64121"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=64121"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=64121"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}